trimethoprim has been researched along with Parkinson Disease in 6 studies
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.
trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Conventional symptomatic treatment for Parkinson's disease (PD) with long-term L-3,4-dihydroxyphenylalanine (DOPA) is complicated with development of drug-induced side effects." | 1.42 | Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. ( Broom, L; Cederfjäll, E; Kirik, D, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quintino, L | 2 |
| Manfré, G | 1 |
| Wettergren, EE | 1 |
| Namislo, A | 1 |
| Isaksson, C | 2 |
| Lundberg, C | 2 |
| Cederfjäll, E | 1 |
| Broom, L | 1 |
| Kirik, D | 1 |
| Tai, K | 1 |
| Gussing, F | 1 |
| Peace, N | 1 |
| Caranasos, GJ | 1 |
| Stewart, RB | 1 |
| Cluff, LE | 1 |
| Osuntokun, BO | 1 |
| Bademosi, O | 1 |
| Ogunremi, K | 1 |
| Wright, SG | 1 |
1 review available for trimethoprim and Parkinson Disease
| Article | Year |
|---|---|
Clinically desirable drug interactions.
Topics: Aminoglycosides; Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Ba | 1985 |
5 other studies available for trimethoprim and Parkinson Disease
| Article | Year |
|---|---|
Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Escherichia coli; Escherichia coli Proteins; Fema | 2013 |
Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Biomarkers; Cell Line; Corpus Striatum; Dependovirus; Dihydroxyphenylalan | 2015 |
Destabilizing domains mediate reversible transgene expression in the brain.
Topics: Animals; Anti-Infective Agents; Bacterial Proteins; Brain; Cell Line, Tumor; Escherichia coli; Femal | 2012 |
Trimethoprim and parkinsonism.
Topics: Humans; Male; Parkinson Disease; Trimethoprim | 1982 |
Neuropsychiatric manifestations of typhoid fever in 959 patients.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chloramphenicol; Female; Humans; Infant; Male; Men | 1972 |